The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing
Open accessAbstract
CRISPR-mediated genome editing efficiently corrected cardiac abnormalities associated with DMD in human engineered heart tissue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.038 · Cited by 4,761
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
Self-citationHigh-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K. (2016) · Nature · doi:10.1038/nature16526 · Cited by 2,673
Rationally engineered Cas9 nucleases with improved specificity
Slaymaker, I. M., Gao, L., Zetsche, B., Scott, D. A., Yan, W. X., & Zhang, F. (2016) · Science · doi:10.1126/science.aad5227 · Cited by 2,414
Improving CRISPR-Cas nuclease specificity using truncated guide RNAs
Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2808 · Cited by 1,993 · cited 1×
“In addition, several new approaches have been reported to minimize potential off-target effects and/or to improve the specificity of the CRISPR/Cas9 system, including titration of dosage of Cas9 and guide RNA (35), paired Cas9 nickases (36–38), truncated guide RNAs (39), and high-fidelity (40) or enhanced Cas9 (41).”
BackgroundMali, P., Aach, J., Stranges, P. B., Esvelt, K. M., Moosburner, M., Kosuri, S., Yang, L., & Church, G. M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2675 · Cited by 1,752
Double-Strand Break End Resection and Repair Pathway Choice
Symington, L. S., & Gautier, J. (2011) · Annual Review of Genetics · doi:10.1146/annurev-genet-110410-132435 · Cited by 1,493
In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy
Nelson, C. E., Hakim, C. H., Ousterout, D. G., Thakore, P. I., Moreb, E. A., Rivera, R. M. C., Madhavan, S., Pan, X., Ran, F. A., Yan, W. X., et al. (2016) · Science · doi:10.1126/science.aad5143 · Cited by 1,144
In vivo gene editing in dystrophic mouse muscle and muscle stem cells
Tabebordbar, M., Zhu, K., Cheng, J. K. W., Chew, W. L., Widrick, J. J., Yan, W. X., Maesner, C., Wu, E. Y., Xiao, R., Ran, F. A., et al. (2016) · Science · doi:10.1126/science.aad5177 · Cited by 1,046
Tohyama, S., Hattori, F., Sano, M., Hishiki, T., Nagahata, Y., Matsuura, T., Hashimoto, H., Suzuki, T., Yamashita, H., Satoh, Y., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2012.09.013 · Cited by 1,037
Correction of a pathogenic gene mutation in human embryos
Ma, H., Marti-Gutierrez, N., Park, S.-W., Wu, J., Lee, Y., Suzuki, K., Koski, A., Ji, D., Hayama, T., Ahmed, R., et al. (2017) · Nature · doi:10.1038/nature23305 · Cited by 992
Long, C., Amoasii, L., Mireault, A. A., McAnally, J. R., Li, H., Sanchez-Ortiz, E., Bhattacharyya, S., Shelton, J. M., Bassel-Duby, R., & Olson, E. N. (2016) · Science · doi:10.1126/science.aad5725 · Cited by 937
Self-citationEvidence-based path to newborn screening for Duchenne muscular dystrophy
Mendell, J. R., Shilling, C., Leslie, N. D., Flanigan, K. M., al‐Dahhak, R., Gastier‐Foster, J., Kneile, K., Dunn, D. M., Duval, B., Aoyagi, A., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23528 · Cited by 813
Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects
Shen, B., Zhang, W., Zhang, J., Zhou, J., Wang, J., Chen, L., Wang, L., Hodgkins, A., Iyer, V., Huang, X., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2857 · Cited by 769
Prevention of muscular dystrophy in mice by CRISPR/Cas9–mediated editing of germline DNA
Long, C., McAnally, J. R., Shelton, J. M., Mireault, A. A., Bassel-Duby, R., & Olson, E. N. (2014) · Science · doi:10.1126/science.1254445 · Cited by 720
Self-citationTiburcy, M., Hudson, J. E., Balfanz, P., Schlick, S., Meyer, T., Chang Liao, M.-L., Levent, E., Raad, F., Zeidler, S., Wingender, E., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.024145 · Cited by 645
Self-citationAartsma-Rus, A., Fokkema, I., Verschuuren, J., Ginjaar, I., van Deutekom, J., van Ommen, G.-J., & den Dunnen, J. T. (2009) · Human Mutation · doi:10.1002/humu.20918 · Cited by 575
Li, H. L., Fujimoto, N., Sasakawa, N., Shirai, S., Ohkame, T., Sakuma, T., Tanaka, M., Amano, N., Watanabe, A., Sakurai, H., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.10.013 · Cited by 471
Self-citationOusterout, D. G., Kabadi, A. M., Thakore, P. I., Majoros, W. H., Reddy, T. E., & Gersbach, C. A. (2015) · Nature Communications · doi:10.1038/ncomms7244 · Cited by 470
Bengtsson, N. E., Hall, J. K., Odom, G. L., Phelps, M. P., Andrus, C. R., Hawkins, R. D., Hauschka, S. D., Chamberlain, J. R., & Chamberlain, J. S. (2017) · Nature Communications · doi:10.1038/ncomms14454 · Cited by 387
Young, C. S., Hicks, M. R., Ermolova, N. V., Nakano, H., Jan, M., Younesi, S., Karumbayaram, S., Kumagai-Cresse, C., Wang, D., Zack, J. A., et al. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.01.021 · Cited by 383
The importance of genetic diagnosis for Duchenne muscular dystrophy
Aartsma-Rus, A., Ginjaar, I. B., & Bushby, K. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2015-103387 · Cited by 369
Dp140: a novel 140 kDa CNS transcript from the dystrophin locus
Lidov, H. G. W., Selig, S., & Kunkel, L. M. (1995) · Human Molecular Genetics · doi:10.1093/hmg/4.3.329 · Cited by 281
Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy
Amoasii, L., Long, C., Li, H., Mireault, A. A., Shelton, J. M., Sanchez-Ortiz, E., McAnally, J. R., Bhattacharyya, S., Schmidt, F., Grimm, D., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan8081 · Cited by 247
Self-citationCRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice
Xu, L., Park, K. H., Zhao, L., Xu, J., El Refaey, M., Gao, Y., Zhu, H., Ma, J., & Han, R. (2016) · Molecular Therapy · doi:10.1038/mt.2015.192 · Cited by 244
CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice
Zhang, Y., Long, C., Li, H., McAnally, J. R., Baskin, K. K., Shelton, J. M., Bassel-Duby, R., & Olson, E. N. (2017) · Science Advances · doi:10.1126/sciadv.1602814 · Cited by 231
Self-citationTherapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches
Fairclough, R. J., Wood, M. J., & Davies, K. E. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3460 · Cited by 229
In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice
Refaey, M. E., Xu, L. M., Gao, Y., Canan, B. D., Adesanya, T. M. A., Warner, S. C., Akagi, K., Symer, D. E., Mohler, P. J., Ma, J., et al. (2017) · Circulation Research · doi:10.1161/circresaha.117.310996 · Cited by 138
Spell Checking Nature: Versatility of CRISPR/Cas9 for Developing Treatments for Inherited Disorders
Wojtal, D., Kemaladewi, D. U., Malam, Z., Abdullah, S., Wong, T. W. Y., Hyatt, E., Baghestani, Z., Pereira, S., Stavropoulos, J., Mouly, V., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.11.012 · Cited by 121
Bostick, B., Yue, Y., Long, C., & Duan, D. (2007) · Circulation Research · doi:10.1161/circresaha.107.162982 · Cited by 120
Self-citationFunctional correction of dystrophin actin binding domain mutations by genome editing
Kyrychenko, V., Kyrychenko, S., Tiburcy, M., Shelton, J. M., Long, C., Schneider, J. W., Zimmermann, W., Bassel‐Duby, R., & Olson, E. N. (2017) · JCI Insight · doi:10.1172/jci.insight.95918 · Cited by 111
Self-citationCardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics
Fayssoil, A., Nardi, O., Orlikowski, D., & Annane, D. (2009) · Heart Failure Reviews · doi:10.1007/s10741-009-9156-8 · Cited by 110
DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy
Gurvich, O. L., Tuohy, T. M. F., Howard, M. T., Finkel, R. S., Medne, L., Anderson, C. B., Weiss, R. B., Wilton, S. D., & Flanigan, K. M. (2007) · Annals of Neurology · doi:10.1002/ana.21290 · Cited by 101
Zhu, P., Wu, F., Mosenson, J. A., Zhang, H., He, T., & Wu, W.-S. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.02.007 · Cited by 94
Maggio, I., Stefanucci, L., Janssen, J. M., Liu, J., Chen, X., Mouly, V., & Gonçalves, M. A. F. V. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1540 · Cited by 81
Maggio, I., Liu, J., Janssen, J. M., Chen, X., & Gonçalves, M. A. F. V. (2016) · Scientific Reports · doi:10.1038/srep37051 · Cited by 81
Iyombe-Engembe, J.-P., Ouellet, D. L., Barbeau, X., Rousseau, J., Chapdelaine, P., Lagüe, P., & Tremblay, J. P. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.58 · Cited by 80
Correction of the Exon 2 Duplication in DMD Myoblasts by a Single CRISPR/Cas9 System
Lattanzi, A., Duguez, S., Moiani, A., Izmiryan, A., Barbon, E., Martin, S., Mamchaoui, K., Mouly, V., Bernardi, F., Mavilio, F., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.02.004 · Cited by 66
Aartsma-Rus, A. M. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-767-5_7 · Cited by 47
Cited by
CRISPR-Cas guides the future of genetic engineering
Knott, G. J., & Doudna, J. A. (2018) · Science · doi:10.1126/science.aat5011 · Cited by 1,410
Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy
Amoasii, L., Hildyard, J. C. W., Li, H., Sanchez-Ortiz, E., Mireault, A., Caballero, D., Harron, R., Stathopoulou, T.-R., Massey, C., Shelton, J. M., et al. (2018) · Science · doi:10.1126/science.aau1549 · Cited by 546
Self-citationCRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors
Wang, D., Zhang, F., & Gao, G. (2020) · Cell · doi:10.1016/j.cell.2020.03.023 · Cited by 527
Therapeutic approaches for cardiac regeneration and repair
Hashimoto, H., Olson, E. N., & Bassel-Duby, R. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0036-6 · Cited by 415
Self-citationThe Driving Force: Nuclear Mechanotransduction in Cellular Function, Fate, and Disease
Maurer, M., & Lammerding, J. (2019) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-060418-052139 · Cited by 277
Metadata
- Authors
- Long, C., Li, H., Tiburcy, M., Rodriguez-Caycedo, C., Kyrychenko, V., Zhou, H., Zhang, Y., Min, Y.-L., Shelton, J. M., Mammen, P. P. A., Liaw, N. Y., Zimmermann, W.-H., Bassel-Duby, R., Schneider, J. W., & Olson, E. N.
- Venue
- Science Advances
- Published
- 2018-01-05
- Volume
- 4
- Issue
- 1
- Pages
- eaap9004-eaap9004
- ISSN
- 2375-2548 (ISSN-L)
- OpenAlex
- W2793661486
- Cited by
- 258
- References
- 43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.